FDA urges USPTO to tackle rising drug costs

The US Food and Drug Administration (FDA) has urged the US Patent and Trademark Office (USPTO) to curb drug costs in the wake of President Joe Biden’s plan to promote competition in the pharmaceutical sector.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FDA approves milestone biosimilar insulin drug

29 July 2021 The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.

Americas

FDA to grant licence to Chinese-owned Advion for COVID-19 diagnostic patent

13 November 2020 The US Food and Drug Administration will today announce that it plans to grant a Chinese-owned testing company an exclusive worldwide licence for a US government-owned patent covering a diagnostic test for the rapid detection of COVID-19.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

FDA urges USPTO to tackle rising drug costs

More on this story

Editor's picks

Editor's picks

More features